Lilly’s decision comes as the FDA has indicated potentially higher approval standards for drugs meant to preserve muscle in ...
Two months after its treatment for Duchenne-related cardiomyopathy was rejected, the company aligned with the agency on a ...
Decades of slow-moving research, along with broader failures of the healthcare system, have left millions of people in daily ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback